Sonnet BioTherapeutics (SONN)

• Market cap: $38.2M
• 1 day: -5.08%
• 5 days: 53.42%
• 1 month: 58.19%
• 3 months: 378.63%
• 6 months: 302.88%
• Year to date: 250%
• 1 year: -19.42%
• 5 years: -99.91%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Employees: 13

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

13% more funds holding

Funds holding: 8 [Q1] → 9 (+1) [Q2]

4% more capital invested

Capital invested by funds: $216K [Q1] → $224K (+$7.63K) [Q2]

0.45% more ownership

Funds ownership: 5.25% [Q1] → 5.7% (+0.45%) [Q2]